Literature DB >> 6266117

Canine bile duct carcinoma.

A K Patnaik, A I Hurvitz, P H Lieberman, G F Johnson.   

Abstract

Twenty-four adenocarcinomas of the hepatobiliary system were found among 110 primary hepatic neoplasms: 22 of these were intrahepatic, one involved the extrahepatic bile duct and one the gall bladder. Histologically, 10 intrahepatic neoplasms were classified as cholangiocarcinoma, and 12 as bile duct cystadenocarcinoma. The former were characterized by tubular structures lined by anaplastic cuboidal or columnar cells with diffuse fibrous stroma, and the latter by multiple cystic structures with papillary and solid areas. Half the bile duct cystadenocarcinomas showed benign cysts and transition to adenocarcinomas. This was seen in only one case of cholangiocarcinoma. The extrahepatic bile duct carcinoma was characterized by tubular structures lined with flattened cuboidal cells with scant stroma. The gall bladder adenocarcinoma contained many acinar structures lined with columnar or cuboidal cells and separated by thin stroma. Distant metastasis was found in 87.5% (21 of 24) sites of metastasis.

Entities:  

Mesh:

Year:  1981        PMID: 6266117     DOI: 10.1177/030098588101800403

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  3 in total

1.  Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors.

Authors:  Jessica R Kinsey; Stephen D Gilson; Joe Hauptman; Steve J Mehler; Lauren R May
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

2.  Cholecystadenocarcinoma in a cat.

Authors:  P Foley; L Miller; K Graham; J Bellamy
Journal:  Can Vet J       Date:  1998-06       Impact factor: 1.008

3.  Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.

Authors:  Cleo P Rogatko; Chick Weisse; Tobias Schwarz; Allyson C Berent; Marcio A Diniz
Journal:  J Vet Intern Med       Date:  2021-05-06       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.